Last checked at 15 Jul 2014 07:00
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
New research delivered at AAIC
Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in drug development, welcomes the two scientific posters (available for review by following the links below) presented yesterday at the Alzheimer's Association International Conference ("AAIC") in Copenhagen highlighted the potential cost savings UK GP practices could achieve by more accurate assessment of patients who present with Subjective Memory Complaints ("SMC").
One poster shows that GP practices can reduce diagnostic costs by 40% by routinely using Cantab Mobile from a calculated average of £42,210 per cohort of 100 SMC patients to £25,666 [1]. Cantab Mobile is a proprietary iPad test that can detect the earliest clinically-relevant signs of memory loss associated with dementia.
The second poster compares three of the most popular tests used within primary care to assess cognitive impairment and concludes that using a more sensitive and specific cognitive assessment such as Cantab Mobile has the potential to be highly cost-effective, by better supporting appropriate decision making and onward referral, through facilitating more accurate primary care triage of cognition, reversible causes and depression.
The two posters are based on the latest economic models developed by researchers at Cambridge Cognition and York Health Economic Consortium, University of York using data from published literature and cost sources. The research team has factored in: 1) the likelihood of different groups consulting their GPs with SMC, including dementia, mild cognitive impairment (MCI), depression and the 'worried well'; 2) the assumption GPs follow current NHS clinical guidelines; and 3) the NHS reference cost for the dementia diagnostic pathway.
The conference is held from the 12th July to the 17th July.
Nick Kerton, Chief Executive Officer of Cambridge Cognition, said: "AAIC is the largest global forum for the dementia research community and brings together over 4,500 professionals from more than 80 countries worldwide. We are pleased to be amongst these thought leaders and that Cantab Mobile is at the forefront of research in this area and that the use of Cantab Mobile by GPs can bring tangible benefits to patients, GPs and the NHS."
Enquiries:
Cambridge Cognition Holdings plc | www.cambridgecognition.com |
Nick Kerton, Chief Executive Officer | Tel: 01223 810 700 |
Nick Walters, Chief Financial Officer | |
finnCap Ltd (Nomad and Broker) | Tel: 020 7220 0500 |
Matthew Robinson/Henrik Persson/Simon Hicks | (Corporate Finance) |
Elizabeth Johnson | (Corporate Broking) |
Walbrook PR Ltd | Tel: 020 7933 8780 or camcog@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Editors' Notes
References to the two posters:
1. Link to the PDF file of technical poster:
'Modelling the economic impact of Cantab Mobile use in UK primary care in the dementia diagnosis pathway.'
http://www.cambridgecognition.com/file-uploads/Final_Poster_Housden_Model_UK_primary_care-pp070714-iii.pdf
2. Link to PDF file of technical poster:
'The sensitivity and specificity of computerised or paper and pencil cognitive assessments
used in primary care impacts the cost-effectiveness of the dementia diagnostic pathway'.
http://www.cambridgecognition.com/file-uploads/Poster_Rous_SensSpec_cog_Ax.pdf